MIP Discovery Secures £7M Series A Funding for Cell and Gene Therapy Advancements
February 21, 2024, 9:44 am
MIP Discovery, a UK-based developer of synthetic affinity reagents for cell and gene therapies, has closed a £7 million Series A financing round led by Mercia Ventures. The funding will drive commercialization efforts and support the expansion of expertise in the field.
MIP Discovery's non-biological affinity reagents offer a new approach to downstream processing in the cell and gene therapy space, providing advanced tools for viral vector characterization, purification, and quality control processes. These synthetic antibody alternatives aim to improve the efficiency and affordability of manufacturing advanced therapies, making them more accessible to patients worldwide.
CEO Stephane Argivier expressed confidence in the company's technology and commercial strategy, highlighting the success of their synthetic antibody alternatives in diagnostic applications and the growing interest in their expertise within the cell and gene therapy sector. With the support of investors like Mercia Ventures and Calculus Capital, MIP Discovery aims to play a key role in advancing the development and production of life-changing therapies on a global scale.
By leveraging sophisticated synthetic chemistry approaches, MIP Discovery is well-positioned to address the evolving needs of the rapidly growing cell and gene therapy market. Their innovative reagents hold significant potential to overcome bottlenecks in therapy development and production, paving the way for more efficient and cost-effective treatments for patients in need.
To learn more about MIP Discovery's contributions to the cell and gene therapy field, visit their website at https://mipdiscovery.com/cell-and-gene-therapy-enablers/.
MIP Discovery's non-biological affinity reagents offer a new approach to downstream processing in the cell and gene therapy space, providing advanced tools for viral vector characterization, purification, and quality control processes. These synthetic antibody alternatives aim to improve the efficiency and affordability of manufacturing advanced therapies, making them more accessible to patients worldwide.
CEO Stephane Argivier expressed confidence in the company's technology and commercial strategy, highlighting the success of their synthetic antibody alternatives in diagnostic applications and the growing interest in their expertise within the cell and gene therapy sector. With the support of investors like Mercia Ventures and Calculus Capital, MIP Discovery aims to play a key role in advancing the development and production of life-changing therapies on a global scale.
By leveraging sophisticated synthetic chemistry approaches, MIP Discovery is well-positioned to address the evolving needs of the rapidly growing cell and gene therapy market. Their innovative reagents hold significant potential to overcome bottlenecks in therapy development and production, paving the way for more efficient and cost-effective treatments for patients in need.
To learn more about MIP Discovery's contributions to the cell and gene therapy field, visit their website at https://mipdiscovery.com/cell-and-gene-therapy-enablers/.